Clinical Report: Berberine Evaluated for Liver Fat

Overview

A randomized clinical trial found that berberine did not reduce visceral adipose tissue or liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease who did not have diabetes. However, it was associated with reductions in low-density lipoprotein cholesterol and high-sensitivity C-reactive protein.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing concern, particularly among individuals with obesity. Effective treatment options are limited, and understanding the efficacy of potential therapies like berberine is crucial for clinical practice. This study contributes to the evidence base regarding the role of berberine in managing liver fat content and associated metabolic parameters, highlighting the need for more effective treatments.

Data Highlights

No statistically significant differences were observed between the berberine and placebo groups in changes to visceral adipose tissue area or liver fat content after 6 months, indicating that berberine may not be effective for these primary outcomes.

Key Findings

• Berberine did not significantly reduce visceral adipose tissue or liver fat content compared to placebo.
• There were no differences in primary outcomes across various subgroups defined by age, sex, and metabolic status.
• Berberine was associated with greater reductions in low-density lipoprotein cholesterol and apolipoprotein B compared to placebo.
• Safety profile of berberine was excellent, with similar rates of adverse events in both groups.
• Post hoc analyses indicated more pronounced lipid reductions in patients with higher baseline hs-CRP levels. Findings were exploratory and should be interpreted with caution.

Clinical Implications

Clinicians should be aware that while berberine may lower certain lipid parameters, it does not effectively reduce liver fat or visceral adipose tissue in patients with MASLD. Current guidelines emphasize lifestyle interventions and validated pharmacotherapies over unproven supplements like berberine, and further research is needed to explore its potential benefits.

Conclusion

This study highlights the limitations of berberine in treating liver fat content in obesity-related metabolic disorders, reinforcing the need for evidence-based approaches in managing MASLD and the importance of exploring more effective treatment options.

References

1. EASL-EASD-EASO, EASL Campus, 2024 -- Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
2. The Journal of Infectious Diseases, 2023 -- Decanoylcarnitine Improves Liver Mitochondrial Dysfunction in Hepatitis B Virus Infection by Enhancing Fatty Acid β-Oxidation
3. Archives of Toxicology, 2021 -- Synergistic Effects of Steatotic and Non-Steatotic Pesticide Combinations on Triglyceride Accumulation in HepaRG Cells
4. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Association of Liver Fat Accumulation with Elevated Insulin Secretion Regardless of Total, Visceral, and Pancreatic Fat Levels
5. Drugs - Real World Outcomes — Association Between Objective Clinical Measures and Patient-Reported Outcomes in Nonalcoholic Fatty Liver Disease Management with Essential Phospholipids: Insights from a Pooled Analysis of Observational Studies
6. Berberine is safe and effective in lowering lipoprotein cholesterol levels in metabolic dysfunction-associated steatotic liver disease
7. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)